Busy AstraZeneca inks yet another big COVID vaccine deal, this time with EU UK books COVID-19 vaccine doses from J&J and Novavax and backs new clinical trials COVID-19 has accelerated the adoption of AI. Executives from Google Cloud, Suki and Olive spell out why Philips deploys hospital monitor kits to ramp-up ICU capacity against COVID-19 On heels of U.S. pact, Johnson & Johnson advances COVID vaccine talks with Europe How AI can help payers navigate a coming wave of delayed and deferred care CureVac banks $213M IPO to push COVID-19 vaccine, boost manufacturing Sinopharm shares phase 2 data on inactivated COVID-19 vaccine The unexpected ways AI is impacting the delivery of care, including for COVID Healthcare roundup: Biden urges governors to mandate wearing masks Biopharma roundup: Sinopharm vaccine data comes with caveat; U.S. official pledges free shots Featured Story | By Eric Sagonowsky As Johnson & Johnson, Sanofi and GlaxoSmithKline move ahead in advanced COVID-19 vaccine supply negotiations with the European Union, AstraZeneca has signed into the union’s first finalized agreement. read more |
| |
|---|
|
Top Stories By Arlene Weintraub The U.K. government's two new deals with J&J and Novavax bring its stockpile of potential COVID-19 vaccines to 340 million doses from six companies. J&J and Novavax will expand their clinical trials in the U.K., too, as the government pledges to get the vaccines on the market by mid-2021 if they succeed. read more By Heather Landi The COVID-19 pandemic has had unpredictable impacts on the healthcare industry. What many industry stakeholders had not counted on was the rapid adoption of artificial intelligence during the health crisis. During a Fierce AI week virtual panel, executives from Google Cloud, Suki and Olive spell out what's driving the demand for AI and what's next for healthcare innovation. read more By Conor Hale The kits can connect 20 standard hospital beds to a central patient monitoring station and be up and running in an average of five hours. read more By Eric Sagonowsky Just one week after inking a COVID-19 vaccine deal with the U.S. for 100 million doses, Johnson & Johnson is moving forward with negotiations on a deal twice that size with the European Union. In details unveiled Thursday, J&J is in talks to supply the EU with 200 million doses of its coronavirus vaccine candidate—if the program succeeds in testing. read more By Robert King Experts say that AI and machine learning could help insurers navigate future surges of healthcare costs that could arise due to the pandemic. read more By Amirah Al Idrus On the heels of a $640 million private round, Germany’s CureVac has netted $213 million in its Nasdaq debut. The bulk of the proceeds will bankroll its mRNA vaccine for COVID-19, with the rest going to manufacturing, platform development and other programs. The company also picked up another $118 million through a private placement to longtime investor, Dietmar Hopp. read more By Nick Paul Taylor Sinopharm has published clinical data on its adjuvanted SARS-CoV-2–inactivated virus vaccine. The phase 1 and 2 results suggest the vaccine may be safe, tolerable and capable of triggering production of antibodies against the pandemic coronavirus. read more By Tina Reed Machines are beginning to outshine their human counterparts as AI is applied to an increasing number of healthcare tasks, experts said during a recent Fierce AI event. read more By Healthcare Staff Follow along with the latest COVID-19 news straight from the Fierce Healthcare team. read more By Eric Sagonowsky, Angus Liu, Kyle Blankenship, Conor Hale, Fraiser Kansteiner The EU tapped AstraZeneca for advance purchase of 300 million shots. J&J is in talks to deploy 200 million vaccines to the EU and inked a deal with the U.K. for 30 million. Sinopharm unveiled phase 2 data on its vaccine. The U.S. is looking to supply COVID-19 shots with zero copay. And the FDA rejected Henry Ford Health System's bid for hydroxychloroquine use. read more |
